Literature DB >> 26938858

Function of Deubiquitinating Enzyme USP14 as Oncogene in Different Types of Cancer.

Ying Zhu1, Chaoxiong Zhang, Changxin Gu, Qiang Li, Ning Wu.   

Abstract

BACKGROUND/AIMS: Non-small cell lung cancer (NSCLC) tissues overexpress USP14, which promotes tumor cell proliferation and is associated with shorter overall survival time.
METHODS: The expression of USP14 was assayed in many types of cancers. USP14 was up-and down-regulated using appropriate plasmid or lentiviral vector constructs and its effects on proliferation, cell colony number, and apoptosis rate were measured. A human NSCLC cell line was inoculated into nude mice and the survival rates were recorded.
RESULTS: We found USP14 amplification and overexpression in many different cancers. The overexpression of USP14 in USP14 low-expression cell lines promoted cell proliferation and migration, whereas USP14 downregulation suppressed tumor cell proliferation, decreased tumor cell colony number, increased apoptosis rate, and decreased cell migration and invasion.
CONCLUSION: USP14 plays an oncogenic role in various types of cancer, and may thus represent a new cancer therapy target.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26938858     DOI: 10.1159/000443051

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  15 in total

1.  Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma.

Authors:  Yang Yu; Yanling Zhao; Yihui Fan; Zhenghu Chen; Hui Li; Jiaxiong Lu; Kevin Guo; Sarah E Woodfield; Sanjeev A Vasudevan; Jianhua Yang; Jed G Nuchtern
Journal:  Mol Cancer Ther       Date:  2019-04-08       Impact factor: 6.261

Review 2.  The role of ubiquitination in tumorigenesis and targeted drug discovery.

Authors:  Lu Deng; Tong Meng; Lei Chen; Wenyi Wei; Ping Wang
Journal:  Signal Transduct Target Ther       Date:  2020-02-29

3.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

4.  A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma.

Authors:  Chunle Zhao; Jun Gong; Yu Bai; Taoyuan Yin; Min Zhou; Shutao Pan; Yuhui Liu; Yang Gao; Zhenxiong Zhang; Yongkang Shi; Feng Zhu; Hang Zhang; Min Wang; Renyi Qin
Journal:  Cell Death Differ       Date:  2022-07-29       Impact factor: 12.067

5.  The tumor suppressor role of miR-155-5p in gastric cancer.

Authors:  Shiqing Li; Tao Zhang; Xiaoqing Zhou; Zonghan Du; Fumin Chen; Jun Luo; Qingsong Liu
Journal:  Oncol Lett       Date:  2018-06-08       Impact factor: 2.967

Review 6.  Metal-based proteasomal deubiquitinase inhibitors as potential anticancer agents.

Authors:  Xin Chen; Qianqian Yang; Lu Xiao; Daolin Tang; Q Ping Dou; Jinbao Liu
Journal:  Cancer Metastasis Rev       Date:  2017-12       Impact factor: 9.264

Review 7.  Deubiquitination Reactions on the Proteasome for Proteasome Versatility.

Authors:  Ji Yeong Shin; Srinivasan Muniyappan; Non-Nuoc Tran; Hyeonjeong Park; Sung Bae Lee; Byung-Hoon Lee
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

8.  USP14 is a deubiquitinase for Ku70 and critical determinant of non-homologous end joining repair in autophagy and PTEN-deficient cells.

Authors:  Arishya Sharma; Turkeya Alswillah; Isha Kapoor; Pal Debjani; Belinda Willard; Matthew K Summers; Zihua Gong; Alexandru Almasan
Journal:  Nucleic Acids Res       Date:  2020-01-24       Impact factor: 16.971

9.  Primary cilium and its role in tumorigenesis.

Authors:  Hongmei Mao; Yi Sun
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-04-25

10.  USP14 de-ubiquitinates vimentin and miR-320a modulates USP14 and vimentin to contribute to malignancy in gastric cancer cells.

Authors:  Ying Zhu; Yan Zhang; Zhenhua Sui; Yi Zhang; Min Liu; Hua Tang
Journal:  Oncotarget       Date:  2017-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.